Compare ANGO & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANGO | NMAI |
|---|---|---|
| Founded | 1988 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 433.5M |
| IPO Year | 2004 | N/A |
| Metric | ANGO | NMAI |
|---|---|---|
| Price | $10.33 | $13.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | ★ 513.0K | 109.2K |
| Earning Date | 04-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | ★ 81.92 | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | ★ $291,010,000.00 | N/A |
| Revenue This Year | $9.51 | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | ★ N/A | $21.39 |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $8.36 | $11.31 |
| 52 Week High | $13.99 | $13.96 |
| Indicator | ANGO | NMAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 68.08 |
| Support Level | $9.62 | $13.43 |
| Resistance Level | $11.06 | $13.90 |
| Average True Range (ATR) | 0.56 | 0.25 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 37.04 | 94.41 |
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.